The invention relates to a composition containing i) a DPP-4 inhibitor selected from an extract of
dandelion (Taraxacum officinale), an extract of
white mulberry (Morus alba), an extract of
bitter melon (
Momordica charantia), a
hydrolysate of
yeast (
Saccharomyces cerevisiae), an extract of garlic (
Allium sativum), an extract of grape (
Vitis vinifera), an extract of turmeric (
Curcuma longa), an extract of horseradish tree (
Moringa oleifera) and an extract of fenugreek (
Trigonella foenum-graecum); and ii) a GLP-1 analogue selected from a
hydrolysate from
yeast (
Saccharomyces cerevisiae), an extract of
white mulberry (Morus alba), an extract of Yerba mate (Ilex paraguariensis), an extract of Arabica coffee (
Coffea arabica), an extract of purslane (
Portulaca oleracea), an extract of
bitter melon (
Momordica charantia), an extract of queen's crape myrtle (Lagertroemia speciosa), an extract of apple (
Malus domestica), an extract of cinnamon (
Cinnamomum verum) and an extract of fenugreek (
Trigonella foenum-graecum); and iii) a GLP-1
secretion promoter selected from
inulin,
gum arabic, an extract of
bitter melon (
Momordica charantia), an extract of purslane (
Portulaca oleracea), an extract of common barberry (
Berberis vulgaris), an extract of arabica coffee (
Coffea arabica), an extract of Dahurian angelica (
Angelica dahurica), an extract of turmeric (
Curcuma longa) and an extract of fenugreek (
Trigonella foenum-graecum), wherein, from each group i)-iii), at least one ingredient is selected and in total at least three different ingredients are selected.